 |
Diagnosing and Treating Male LUTS in the Primary Care Setting: A Case Series CME/CE Author Information and Disclosures Release Date: May 2, 2008; Valid for credit through May 2, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 nursing contact hours (0.5 contact hours are in the area of pharmacology) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Review typical clinical features of urinary symptoms associated with benign prostatic hyperplasia (BPH)
- Discuss the direct and indirect impact of lower urinary tract symptoms (LUTS) on quality of life in men
- Conduct an
appropriate history and clinical examination of men presenting with symptoms consistent with LUTS
- Review the typical sequence of treatment options for LUTS due to BPH in the primary care setting, including medical and nonmedical therapies and guidelines for referral
Authors and Disclosures Claus G. Roehrborn, MD
Disclosure: Claus G. Roehrborn, MD, has disclosed that he has received grants for educational activities from GlaxoSmithKline, sanofi-aventis, Spectrum, Lilly, Aeterna Zentaris, Pfizer, and AMS. Dr. Roehrborn has also disclosed that he has served as an advisor or consultant to GlaxoSmithKline, sanofi-aventis, Spectrum, Lilly, Aeterna Zentaris, Pfizer, and AMS. Scott A. MacDiarmid, MD
Disclosure: Scott A. MacDiarmid,
MD, has disclosed that he has served as an advisor or consultant to Pfizer, Watson, Novartis, Allergan, and Astellas. John T. Wei, MD, MS
Disclosure: John T. Wei, MD, MS, has disclosed that he has received grants for clinical research from sanofi-aventis and Envisioneer. Dr. Wei has also disclosed that he has served as an advisor or consultant to sanofi-aventis, Gen-Probe, and Envisioneer, and that he has served as a
speaker for AMS. David McNeel
Disclosure: David McNeel has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
